Erasca (ERAS) Current Assets (2020 - 2026)
Erasca's (ERAS) quarterly Current Assets came in at $253.8 million in Q1 2026, down 19.34% YoY from $314.6 million in Q1 2025, and down 11.34% on a QoQ basis from $286.2 million in Q4 2025.
Erasca (ERAS) Current Assets (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Current Assets data on file, last reported at $253.8 million in Q1 2026.
- Quarterly Current Assets fell 19.34% year-over-year to $253.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $253.8 million (down 19.34% YoY) and the FY2025 annual result came in at $286.2 million, down 7.3% from the prior year.
- Current Assets fell to $253.8 million in Q1 2026, from $286.2 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $444.5 million in Q4 2022 to a low of $253.8 million in Q1 2026.
- A 5-year average of $339.5 million and a median of $320.7 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets soared 93.33% — and 2023, when it decreased 27.86%.
- Tracing ERAS's Current Assets over 5 years: stood at $444.5 million in 2022, then declined by 27.86% to $320.7 million in 2023, then dropped by 3.71% to $308.8 million in 2024, then retreated by 7.3% to $286.2 million in 2025, then fell by 11.34% to $253.8 million in 2026.
- The last three Current Assets figures came in at $253.8 million (Q1 2026), $286.2 million (Q4 2025), and $299.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 278.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 278.44 Mn |
| Mar 31, 2026 | 253.78 Mn |
| Dec 31, 2025 | 286.24 Mn |
| Sep 30, 2025 | 299.93 Mn |
| Jun 30, 2025 | 310.66 Mn |
| Mar 31, 2025 | 314.62 Mn |
| Dec 31, 2024 | 308.79 Mn |
| Sep 30, 2024 | 330.17 Mn |
| Jun 30, 2024 | 418.01 Mn |
| Mar 31, 2024 | 306.62 Mn |
| Dec 31, 2023 | 320.68 Mn |
| Sep 30, 2023 | 305.97 Mn |
| Jun 30, 2023 | 323.85 Mn |
| Mar 31, 2023 | 397.88 Mn |
| Dec 31, 2022 | 444.50 Mn |
| Sep 30, 2022 | 365.75 Mn |
| Jun 30, 2022 | 381.42 Mn |
| Mar 31, 2022 | 403.37 Mn |
| Dec 31, 2021 | 420.02 Mn |
| Sep 30, 2021 | 492.31 Mn |